Aug 13, 2024 / 12:30PM GMT
Renee Aguiar-Lucander - Calliditas Therapeutics AB - Chief Executive Officer
Thank you very much. Welcome to our Q2 2024 report. My name is Renée Aguiar-Lucander, CEO of Calliditas. And I'm joined today by Richard Philipson, Chief Medical Officer; Fredrik Johansson, our Chief Financial Officer; and Maria Tornsen, President of North America.
Next page, please. I'd like to draw your attention to disclaimer notice, which covers forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended, and I refer to our public filings, including those containing risk factors.
Next page, please. So I'd like to review some of the key events in Q2, which included the conclusion of our Phase 3 study, NefIgArd, with the readout of the open-label extension from which we reported nine months efficacy and safety data, similar to that observed in the active arm of the Phase 3 trial for those patients who are retreated with Nefecon after 15 months of observation.
In April, we reported positive top line data from our Phase 2 proof-of
Q2 2024 Calliditas Therapeutics AB Earnings Call Transcript
Aug 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers